Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0042 | 0 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0087 | 0.4666 | 0.1439 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0087 | 0.4666 | 0.3536 |
Chlamydia trachomatis | glutamine binding protein | 0.0042 | 0 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0042 | 0 | 0.5 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0078 | 0.377 | 0.245 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0137 | 1 | 1 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0042 | 0 | 0.5 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0042 | 0 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0042 | 0 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0119 | 0.8068 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.